CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Depression is a pervasive mental health condition affecting millions of people worldwide. It can manifest in various ways, from persistent sadness to a lack of energy or interest in daily activities.

Researchers at CU Anschutz are studying the effect of psychedelic mushrooms on patients with treatment-resistant depression.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

an inhalable treatment for treatment-resistant depression (TRD), demonstrating a significant placebo-adjusted reduction in depression scores as measured by the MADRS scale on Day 8. The trial ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Earlier phases of the trial showed promising results, with a single 25mg dose of COMP360 psilocybin, combined with psychological support, significantly reducing depressive symptoms after three weeks, ...